Ernexa Therapeutics (ERNAW) Long-Term Deferred Tax (2012 - 2020)

Ernexa Therapeutics (ERNAW) has 11 years of Long-Term Deferred Tax data on file, last reported at $34000.0 in Q4 2020.

• Quarterly Long-Term Deferred Tax fell 87.59% year-over-year to $34000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $34000.0 (down 87.59% YoY) and the FY2020 annual result came in at $34000.0, down 87.59% from the prior year.
• Long-Term Deferred Tax fell to $34000.0 in Q4 2020, from $85000.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $1.3 million in Q1 2016 to a low of $23000.0 in Q4 2018.
• A 5-year average of $597333.3 and a median of $584000.0 in 2018 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2018 — Long-Term Deferred Tax tumbled 97.03% — and 2019, when it soared 1091.3%.
• Tracing ERNAW's Long-Term Deferred Tax over 5 years: stood at $904000.0 in 2016, then fell by 14.27% to $775000.0 in 2017, then plunged by 97.03% to $23000.0 in 2018, then soared by 1091.3% to $274000.0 in 2019, then plunged by 87.59% to $34000.0 in 2020.
• The last three Long-Term Deferred Tax figures came in at $34000.0 (Q4 2020), $85000.0 (Q3 2020), and $239000.0 (Q1 2020), per Business Quant data.